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Scientific objectives
The detection of mutations in tumour tissue is increas-
ingly important to pathologists due to the number of tar-
geted, personalised therapies that are only effective in
tumours displaying specific mutations. At present, much
of the testing to detect these mutations is performed using
individual assays. This has proven to be an effective
method as the number of ‘drugable’ mutations is currently
relatively low. However, the number of targeted therapies
(and therefore targets to be assessed) is expected to rise
significantly. This has led to the development of assays
capable of assessing mutations across multiple gene
panels. Here we assess one new technology (Ion Torrent’s
PGM), comparing the results to those obtained with pyro-
sequencing and Sanger sequencing, both established tech-
nologies used in molecular pathology laboratories.
Technological approach
DNA extracted from 8 cell lines with known TP53
mutations (CCRF-CEM, SW 837, NCI-H23, U251,
MDAMD231, SKBR-3, CALU6, C33a) was sequenced
using Ion Torrent (Ion PGM sequencer, Life Technolo-
gies), Pyrosequencing (PyroMark Q24, Qiagen) and San-
ger sequencing technology.
Results
The Ion Torrent results matched those achieved using
pyrosequencing and Sanger sequencing in all 8 cases.
The results also matched the known mutations for these
cell lines in the TP53UMD mutation database.
Conclusion and recommendations
Results achieved with the Ion Torrent PGM were com-
parable to those seen using pyrosequencing and Sanger
sequencing. As the number and complexity of tests
required to inform clinicians increases technologies such
as this, with high throughput and scope for expansion
may prove beneficial to diagnostic molecular pathology
laboratories.
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